Atrovastatin for Preventing Atrial Fibrillation Following Open Cardiac Valve Repair

Urmia University of Medical Sciences

Status and phase

Completed

Phase 3

Conditions

Heart Valve Diseases

Treatments

Drug: Atorvastatin

Study type

Interventional

Funder types

Other

Identifiers

NCT02084069

UMSU-Cardiology-2

Details and patient eligibility

About

The purpose of the investigation is to determine whether Atrovastatin as anti-inflammatory agent can be effective in preventing from atrial fibrillation incidence in patients whom undergone open cardiac surgery for their heart valve repair.

Enrollment

58 patients

Sex

All

Ages

25+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Greater than 25 y/o
No occurrence of intra- or post-operative cardiopulmonary arrest
Not consuming drugs affecting atrial rhythm
Having sinus rhythm before surgery
Lack of paroxysmal atrial fibrillation history
Only undergo heart valve surgery
Lack of considerable heart ischemia needed atorvastatin use
Routine cares in ward, post-operative ward, and intensive care unit were done

Exclusion criteria

Lesser than 25 y/o
History of atrial fibrillation
History of taking anti-arrhythmic drugs
History of implementing pacemakers
Severe heart failure
Renal failure
Hepatic failure
Severe pulmonary diseases
Heart block or bradyarrhythmia
Routine cares in ward, post-operative ward, and intensive care unit were not done
Performing concomitant cardiac surgery except valve repair
Having considerable heart ischemia needed atorvastatin use